drugset / Trial / NCT00005017
Effectiveness and Safety of Epivir/Ziagen/Zerit (3TC/ABC/d4T) Versus Epivir/Ziagen/Sustiva (3TC/ABC/EFV) Versus Epivir/Ziagen/Agenerase/Norvir (3TC/ABC/APV/RTV) in HIV Patients Who Have Never Received Treatment
Treatment
Summary
The purpose of this study is to see how effective and safe it is to give 1 of the 3 following treatments to patients who may not have received anti-HIV treatment: 1) lamivudine (3TC)/abacavir (ABC)/stavudine (d4T); 2) 3TC/ABC/efavirenz (EFV); or 3) 3TC/ABC/amprenavir (APV)/ritonavir (RTV).
Timeline
- Start
- —
- Primary completion
- —
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Amprenavir | Other / unclassified | — | — |
| Subject | Efavirenz | Other / unclassified | — | — |
| Subject | Ritonavir | Other / unclassified | — | — |
| Subject | Stavudine | Other / unclassified | — | — |
| Background | Abacavir | Other / unclassified | — | — |
| Background | Lamivudine | Other / unclassified | — | — |